Our Approach

We leverage the inherent complexity of disease biology to redefine drug targeting and create a new generation of synergistic therapies for common conditions.

Why Synergy?

Simultaneously targeting multiple pathways allows us to address two key types of biological complexity:

Redundancy

In a disease where 2 biological pathways result in the modification of the same disease-driving protein, for instance, blocking only one might have negligible effects. Targeting both can more effectively treat the disease.

Compensation

In a disease that requires the activity of a particular biochemical pathway, blocking one protein to shut down that pathway might trigger the upregulation of a compensatory pathway. Targeting both pathways can block this compensation.

Redundancy and compensation are extremely common biological processes that play a role in numerous diverse diseases. Therapeutics directed at single targets cannot easily address these types of biological complexity, which is why the standard of care for many conditions — including heart disease, cancer, inflammatory disease, and metabolic disease — often includes synergistic drug combinations or multifunctional drugs.

The power of Locksmith®

Leveraging Passkey's proprietary computational genetics and data foundation, Locksmith identifies synergistic target pathways at scale.

Locksmith

In many cases these pathway pairs can be validated with existing drugs, resulting indication expansion and lifecycle extension.

Passkey Therapeutics Launches with Platform to Design Multifunctional Drugs

Bruce Beutel, PhD, who has worked in the drug development industry for over thirty years is ready for a change. He wants to move beyond the single target paradigm, in...

Read more

Passkey Therapeutics launches with $20M to focus on pipeline, partnerships

After establishing its platform, Passkey Therapeutics Inc. is now emerging from stealth to focus on building its pipeline and partnerships...

Read more

Passkey aims to use single drugs for multiple proteins

A trio of biotech and pharma executives with backgrounds in computational chemistry and systems biology are making a bet: that new computational tools will allow them to go after multiple...

Read more

Passkey Therapeutics Raises $20 Million to Advance a New Class of Multifunctional Therapeutics with Proprietary Platform Targeting Rare Combinations of Proteins

Cambridge, MA, October 22, 2024 — Passkey Therapeutics, the pioneer of Synergistic Multifunctional Therapeutics (SMThs), announced today that it has emerged from stealth with $20 million in seed funding led...

Read more